<DOC>
	<DOCNO>NCT01051661</DOCNO>
	<brief_summary>The purpose study characterize safety efficacy GSK Biologicals ' H1N1 flu candidate vaccine GSK2340274A GSK2340273A child 6 month le 10 year age .</brief_summary>
	<brief_title>Safety Efficacy H1N1 Vaccines Children Aged 6 Months Less Than 10 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female child 6 month le 10 year age time first vaccination . `` Less 10 year age '' implies inclusion child reach 10th birthday Day 0 , day first vaccine dose protocol . Written inform consent obtain subject 's parent ( ) /legally acceptable representative ( ) ( LAR ( ) ) ; write informed assent obtain subject appropriate pre local requirement ) . Stable health status define absence health event satisfy definition SAE , change ongoing drug therapy due therapeutic failure symptom drug toxicity , within 1 month prior enrolment . Parent ( ) /LAR ( ) available accessible active surveillance contact . Parent ( ) /LAR ( ) ( ageappropriate , subject ) , investigator 's opinion , comply requirement protocol documented signature inform consent document . Female subject nonchildbearing potential ( premenarche ) may enrol study . Previous vaccination A/California/7/2009 ( H1N1 ) vlike virus vaccine . Medical history physicianconfirmed infection A/California/7/2009 ( H1N1 ) vlike virus . Presence evidence substance abuse neurological psychiatric diagnosis , even stable , deemed investigator render potential subject parent ( ) /LAR ( ) unable/unlikely provide accurate safety report . Presence temperature ≥ 38.0ºC ( ≥ 100.4ºF ) route method , acute symptom great `` mild '' severity schedule date first vaccination . NOTE : The subject may vaccinate later date , provide symptom resolve , vaccination occurs within window specify protocol , eligibility criterion continue satisfy . Diagnosed cancer , treatment cancer , within 3 year . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Receipt systemic glucocorticoid within 1 month prior study enrollment ( first dose study vaccine ) , cytotoxic immunosuppressive drug within 6 month study enrollment . Topical , intraarticular inhale glucocorticoid allow . Receipt immunoglobulins and/or blood product within 6 month study enrollment plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . Persons receive individual dos low molecular weight heparin eligible dos give 24 hour study vaccination . Persons receive prophylactic antiplatelet medication , e.g. , lowdose acetylsalicylic acid , without clinicallyapparent bleeding tendency , eligible . An acute evolve neurological disorder history GuillainBarré syndrome within 6 week receipt seasonal influenza vaccine . Administration license live attenuated vaccine within 4 week first vaccination license inactivated vaccine within 2 week first vaccination . Planned administration vaccine foreseen study protocol Day 0 Day 42 . Routine childhood vaccination exempt delayed , must administer day H1N1 vaccine candidate . Planned use pandemic monovalent A/California/7/2009 ( H1N1 ) vlike virus vaccine study vaccine study period . Planned administration seasonal trivalent influenza vaccine 4 month period follow Day 0 . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day first dose study vaccine , plan use study period . Any known suspected allergy constituent influenza vaccine ( include egg proteins mercurial preservative ) ; history anaphylactictype reaction consumption egg ; history severe adverse reaction previous influenza vaccine . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Influenza</keyword>
	<keyword>H1N1</keyword>
	<keyword>Pandemic</keyword>
</DOC>